As the Federal Trade Commission scrutinizes the pharmaceutical industry, there is growing debate about whether the regulator may next target a deal that some experts say could make it easier for Novo Nordisk to boost production of a key drug — at the expense of competitors, STAT explains. At issue is a complicated transaction sparked by sporadic shortages of one of the world's hottest-selling medications — the weight loss treatment Wegovy. The deal is designed to solve what has been a critical and seemingly intractable problem for the company, but it is also raising questions about fair play and the longer-term effect on consumers.